Meeting
2024 ASCO Annual Meeting
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa.
Authors
Arndt Stahler
Charité– Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany
Arndt Stahler , Dominik Paul Modest , Sebastian Stintzing , Swantje Held , Ludwig Fischer von Weikersthal , Lothar Müller , Ullrich Graeven , Thomas Decker , Tobias Heintges , Christoph Kahl , Werner Scheithauer , Alexander Kiani , Florian Kaiser , Ingo Schwaner , Stefan Fruehauf , Meinolf Karthaus , Tanja Trarbach , Frederik Klauschen , David Horst , Volker Heinemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3529)
DOI
10.1200/JCO.2024.42.16_suppl.3529
Abstract #
3529
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR).
First Author: Kota Ouchi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Retrospective analysis of the real-world demographics, clinical characteristics, and treatment patterns in metastatic CRC among patients treated with encorafenib in combination with cetuximab in the United States.
First Author: Aparna Raj Parikh
Poster
2023 ASCO Annual Meeting
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.
First Author: Anna Maria Rachiglio
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line anti-EGFR or anti-VEGF therapy, tumour sidedness, and survival: Results from the South Australian (SA) Metastatic Colorectal Cancer (mCRC) Registry.
First Author: Tharani Krishnan